KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Net Margin (2020 - 2023)

AbCellera Biologics (ABCL) has disclosed Net Margin for 4 consecutive years, with 513.68% as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Net Margin fell 37494.0% year-over-year to 513.68%, compared with a TTM value of 513.68% through Sep 2024, down 25741.0%, and an annual FY2024 reading of 564.83%, down 17982.0% over the prior year.
  • Net Margin was 513.68% for Q4 2023 at AbCellera Biologics, down from 433.62% in the prior quarter.
  • Across five years, Net Margin topped out at 59.7% in Q2 2020 and bottomed at 513.68% in Q4 2023.
  • Average Net Margin over 4 years is 119.21%, with a median of 21.77% recorded in 2020.
  • The sharpest move saw Net Margin skyrocketed 41442bps in 2022, then crashed -45988bps in 2023.
  • Year by year, Net Margin stood at 56.28% in 2020, then dropped by -24bps to 43.02% in 2021, then crashed by -422bps to 138.75% in 2022, then crashed by -270bps to 513.68% in 2023.
  • Business Quant data shows Net Margin for ABCL at 513.68% in Q4 2023, 433.62% in Q3 2023, and 303.57% in Q2 2023.